Dr Prem Mahendra is the leading private consultant haemato-oncologist in the West Midlands. For more than 25 years she has been providing an unparalleled, empathetic and efficient service for patients with blood cancer, and is passionate about delivering outstanding care. Private patients are seen either at the Priory Hospital, Edgbaston, Birmingham or at the HCA Harborne Hospital, Edgbaston, Birmingham.
She is an NHS consultant at the Queen Elizabeth Hospital, Birmingham.
Areas of expertise are care of patients with:
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Myeloma
- Acute myeloid and lymphoblastic leukaemia
- Chronic lymphocytic and myeloid leukaemia
- Myelodysplasia
- Myeloproliferative disorder
- Waldenstroms macroglobulinaemia
And those undergoing:
- Autologous stem cell transplantation
- Allogeneic stem cell transplantation.
- CAR-T (chimeric antigen receptor-T-cell therapy)
![](https://premmahendra.co.uk/wp-content/uploads/2021/05/Blood_Cancer_UK.jpg)
![](https://premmahendra.co.uk/wp-content/uploads/2021/05/MyelomaUK.jpg)
![Lymphoma_Action](https://premmahendra.co.uk/wp-content/uploads/2021/05/Lymphoma_Action.jpg)
Latest News
Priory Hospital treats first patient with Teclistamab a bispecific antibody treatment for myeloma.
Bispecific T-cell engagers are a new and innovative treatment for myeloma. Two bispecific antibodies Teclistamab and Talquetamab have been approved by the EMA for the...
Exciting new treatment for diffuse-large B-cell lymphoma approved by the European Medicines Agency (EMA).
In July 2023 the EMA approved Glofitamab, one of the most potent single drugs available for the treatment of relapsed/refractory DLBCL. Glofitamab is a CD20xCD3...
Update on mantle cell lymphoma 15 October 2023
For older non-transplant eligible patients’ initial treatment options are VR-CAP (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisolone based on the LYM 3002 phase 3 trial of...